(Post-pandemic Era)-Global The Influenza (Flu) Antiviral Drugs Market Segment Research Report 2023

Report ID: 875312 | Published Date: Apr 2026 | No. of Page: 99 | Base Year: 2025 | Rating: 5
Request Sample Report
Pre-Order Enquiry 
Table of Contents

Global The Influenza (Flu) Antiviral Drugs Market Segment Research Report 2021
1. Research Scope
2. Market Overview
    2.1 Product Introduction, Application, Picture
    2.2 Global The Influenza (Flu) Antiviral Drugs Market by Value
      2.2.1 Global The Influenza (Flu) Antiviral Drugs Revenue by Type
      2.2.2 Global The Influenza (Flu) Antiviral Drugs Market by Value (%)
    2.3 Global The Influenza (Flu) Antiviral Drugs Market by Production
      2.3.1 Global The Influenza (Flu) Antiviral Drugs Production by Type
      2.3.2 Global The Influenza (Flu) Antiviral Drugs Market by Production (%)

3. The Major Driver of The Influenza (Flu) Antiviral Drugs Industry
    3.1 Historical & Forecast Global The Influenza (Flu) Antiviral Drugs Demand
    3.2 Largest Application for The Influenza (Flu) Antiviral Drugs (2017-2027)
    3.3 The Major Downstream Company in China Market 2021

4. Global and Regional The Influenza (Flu) Antiviral Drugs Market
    4.1 Regional Market Size in Terms of Production & Demand (2021)
    4.2 Regional Market Share in Terms of Revenue (2019-2027) 
    4.3 Concentration Ratio (CR5& CR10) of The Influenza (Flu) Antiviral Drugs Market
    4.4 Mergers & Acquisitions, Expansion Plans

5. US The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    5.1 Current and Estimated Production Breakdown by Type
    5.2 Current and Estimated Demand Breakdown by Type
    5.3 Current and Estimated Demand Breakdown by Application
    5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

6. Europe The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    6.1 Current and Estimated Production Breakdown by Type
    6.2 Current and Estimated Demand Breakdown by Type
    6.3 Current and Estimated Demand Breakdown by Application
    6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

7. China The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    7.1 Current and Estimated Production Breakdown by Type
    7.2 Current and Estimated Demand Breakdown by Type
    7.3 Current and Estimated Demand Breakdown by Application
    7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

8. Japan The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    8.1 Current and Estimated Production Breakdown by Type
    8.2 Current and Estimated Demand Breakdown by Type
    8.3 Current and Estimated Demand Breakdown by Application
    8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

9. India The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    9.1 Current and Estimated Production Breakdown by Type
    9.2 Current and Estimated Demand Breakdown by Type
    9.3 Current and Estimated Demand Breakdown by Application
    9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

10. Korea The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    10.1 Current and Estimated Production Breakdown by Type
    10.2 Current and Estimated Demand Breakdown by Type
    10.3 Current and Estimated Demand Breakdown by Application
    10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

11. Southeast Asia The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    11.1 Current and Estimated Production Breakdown by Type
    11.2 Current and Estimated Demand Breakdown by Type
    11.3 Current and Estimated Demand Breakdown by Application
    11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

12. Global The Influenza (Flu) Antiviral Drugs Average Price Trend
    12.1 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in US (2017-2021)
    12.2 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Europe (2017-2021)
    12.3 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in China (2017-2021)
    12.4 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Japan (2017-2021)
    12.5 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in India (2017-2021)
    12.6 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Korea (2017-2021)
    12.7 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Southeast Asia (2017-2021)

13. Industrial Chain (Impact of COVID-19)
    13.1 The Influenza (Flu) Antiviral Drugs Industrial Chain Analysis
    13.2 Downstream
    13.3 Impact of COVID-19
    13.4 Technology Trends of The Influenza (Flu) Antiviral Drugs

14. The Influenza (Flu) Antiviral Drugs Competitive Landscape
     14.1 Pfizer
        14.1.1 Pfizer Company Profiles
        14.1.2 Pfizer Product Introduction
        14.1.3 Pfizer The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.1.4 Strategic initiatives
     14.2 Gilead Sciences
        14.2.1 Gilead Sciences Company Profiles
        14.2.2 Gilead Sciences Product Introduction
        14.2.3 Gilead Sciences The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.2.4 Strategic initiatives
     14.3 Johnson & Johnson
        14.3.1 Johnson & Johnson Company Profiles
        14.3.2 Johnson & Johnson Product Introduction
        14.3.3 Johnson & Johnson The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.3.4 Strategic initiatives
     14.4 Roche
        14.4.1 Roche Company Profiles
        14.4.2 Roche Product Introduction
        14.4.3 Roche The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.4.4 Strategic initiatives
     14.5 AbbVie
        14.5.1 AbbVie Company Profiles
        14.5.2 AbbVie Product Introduction
        14.5.3 AbbVie The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.5.4 Strategic initiatives
     14.6 Sanofi
        14.6.1 Sanofi Company Profiles
        14.6.2 Sanofi Product Introduction
        14.6.3 Sanofi The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.6.4 Strategic initiatives
     14.7 Amgen
        14.7.1 Amgen Company Profiles
        14.7.2 Amgen Product Introduction
        14.7.3 Amgen The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.7.4 Strategic initiatives
     14.8 Novartis
        14.8.1 Novartis Company Profiles
        14.8.2 Novartis Product Introduction
        14.8.3 Novartis The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.8.4 Strategic initiatives
     14.9 Merck & Co. (MSD)
        14.9.1 Merck & Co. (MSD) Company Profiles
        14.9.2 Merck & Co. (MSD) Product Introduction
        14.9.3 Merck & Co. (MSD) The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.9.4 Strategic initiatives
     14.10 GlaxoSmithKline (GSK)
        14.10.1 GlaxoSmithKline (GSK) Company Profiles
        14.10.2 GlaxoSmithKline (GSK) Product Introduction
        14.10.3 GlaxoSmithKline (GSK) The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
        14.10.4 Strategic initiatives
     14.11 Bayer
     14.12 Takeda
     14.13 AstraZeneca
     14.14 Novo Nordisk
     14.15 Teva
     14.16 Bristol-Myers Squibb
     14.17 Boehringer Ingelheim
     14.18 Allergan
     14.19 Eli Lilly
15. Conclusion


List of Tables and Figures

    Figure 1. Total Demand by Application of The Influenza (Flu) Antiviral Drugs Industry (Volume)
    Figure 2. The Influenza (Flu) Antiviral Drugs Production & Demand by Regions in 2021
    Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
    Figure 4. The Top 10 and 5 Players Market Share by The Influenza (Flu) Antiviral Drugs Revenue in 2021
    Figure 5. US The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 6. Production Breakdown by Type (%)
    Figure 7. Demand Breakdown by Type (%)
    Figure 8. Demand Breakdown by Application (%)
    Figure 9. Revenue Breakdown by Type (%)
    Figure 10. Revenue Breakdown by Application (%)
    Figure 11. Europe The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 12. Production Breakdown by Type (%)
    Figure 13. Demand Breakdown by Type (%)
    Figure 14. Demand Breakdown by Application (%)
    Figure 15. Revenue Breakdown by Type (%)
    Figure 16. Revenue Breakdown by Application (%)
    Figure 17. China The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 18. Production Breakdown by Type (%)
    Figure 19. Demand Breakdown by Type (%)
    Figure 20. Demand Breakdown by Application (%)
    Figure 21. Current and Estimated Revenue Breakdown by Type
    Figure 22. Revenue Breakdown by Type (%)
    Figure 23. Revenue Breakdown by Application (%)
    Figure 24. Japan The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 25. Production Breakdown by Type (%)
    Figure 26. Demand Breakdown by Type (%)
    Figure 27. Demand Breakdown by Application (%)
    Figure 28. Revenue Breakdown by Type (%)
    Figure 29. Revenue Breakdown by Application (%)
    Figure 30. India The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 31. Production Breakdown by Type (%)
    Figure 32. Demand Breakdown by Type (%)
    Figure 33. Demand Breakdown by Application (%)
    Figure 34. Revenue Breakdown by Type (%)
    Figure 35. Revenue Breakdown by Application (%)
    Figure 36. Korea The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 37. Production Breakdown by Type (%)
    Figure 38. Demand Breakdown by Type (%)
    Figure 39. Demand Breakdown by Application (%)
    Figure 40. Revenue Breakdown by Type (%)
    Figure 41. Revenue Breakdown by Application (%)
    Figure 42. Southeast Asia The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)
    Figure 43. Current and Estimated Production Breakdown by Type (2017-2027)
    Figure 44. Production Breakdown by Type (%)
    Figure 45. Demand Breakdown by Type (%)
    Figure 46. Revenue Breakdown by Type (%)
    Figure 47. Revenue Breakdown by Application (%)
    Figure 48. Industrial Chain
    Table 1. Top Manufacturers and Market Segmentation
    Table 2. Product Introduction, Application, Picture
    Table 3. The Influenza (Flu) Antiviral Drugs Revenue, by Type (Million USD) (2017-2027)
    Table 4. The Influenza (Flu) Antiviral Drugs Production, by Type (K Unit) (2017-2027)
    Table 5. The Influenza (Flu) Antiviral Drugs Demand (K Unit) by Application (2017-2027)
    Table 6. The Influenza (Flu) Antiviral Drugs Demand (Million USD) by Application (2017-2027)
    Table 7. The Major Downstream Company in China
    Table 8. Regional Market Share in Terms of Production & Demand (2021)
    Table 9. Regional Market Share in Terms of Revenue (2021&2027)
    Table 10. Ranking of Global Top The Influenza (Flu) Antiviral Drugs Companies by Revenue, Concentration Ratio in 2021
    Table 11. Mergers & Acquisitions, Expansion Plans
    Table 12. US The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 13. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 14. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 15. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 16. Current and Estimated Revenue Breakdown by Type
    Table 17. Current and Estimated Revenue Breakdown by Application
    Table 18. Europe The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 19. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 20. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 21. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 22. Current and Estimated Revenue Breakdown by Type
    Table 23. Current and Estimated Revenue Breakdown by Application
    Table 24. China The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 25. Table Current and Estimated Production Breakdown by Type
    Table 26. Current and Estimated Demand Breakdown by Type
    Table 27. Current and Estimated Demand Breakdown by Application
    Table 28. Current and Estimated Revenue Breakdown by Application
    Table 29. Japan The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 30. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 31. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 32. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 33. Current and Estimated Revenue Breakdown by Type
    Table 34. Current and Estimated Revenue Breakdown by Application
    Table 35. India The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 36. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 37. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 38. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 39. Current and Estimated Revenue Breakdown by Type
    Table 40. Current and Estimated Revenue Breakdown by Application
    Table 41. Korea The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 42. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 43. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 44. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 45. Current and Estimated Revenue Breakdown by Type
    Table 46. Current and Estimated Revenue Breakdown by Application
    Table 47. Southeast Asia The Influenza (Flu) Antiviral Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 48. Table Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 49. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 50. Current and Estimated Revenue Breakdown by Type
    Table 51. Current and Estimated Revenue Breakdown by Application
    Table 52. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in US (2017-2021)
    Table 53. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in Europe (2017-2021)
    Table 54. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in China (2017-2021)
    Table 55. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in Japan (2017-2021)
    Table 56. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in India (2017-2021)
    Table 57. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in Korea (2017-2021)
    Table 58. Market Price (USD/Unit) for Each Type of The Influenza (Flu) Antiviral Drugs in Southeast Asia (2017-2021)
    Table 59. Key Downstream Customer in Each Application Field
    Table 60. Pfizer Profiles
    Table 61. Pfizer The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 62. Pfizer The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 63. Pfizer Strategic initiatives
    Table 64. Gilead Sciences Profiles
    Table 65. Gilead Sciences The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 66. Gilead Sciences The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 67. Gilead Sciences Strategic initiatives
    Table 68. Johnson & Johnson Profiles
    Table 69. Johnson & Johnson The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 70. Johnson & Johnson The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 71. Johnson & Johnson Strategic initiatives
    Table 72. Roche Profiles
    Table 73. Roche The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 74. Roche The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 75. Roche Strategic initiatives
    Table 76. AbbVie Profiles
    Table 77. AbbVie The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 78. AbbVie The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 79. AbbVie Strategic initiatives
    Table 80. Sanofi Profiles
    Table 81. Sanofi The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 82. Sanofi The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 83. Sanofi Strategic initiatives
    Table 84. Amgen Profiles
    Table 85. Amgen The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 86. Amgen The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 87. Amgen Strategic initiatives
    Table 88. Novartis Profiles
    Table 89. Novartis The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 90. Novartis The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 91. Novartis Strategic initiatives
    Table 92. Merck & Co. (MSD) Profiles
    Table 93. Merck & Co. (MSD) The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 94. Merck & Co. (MSD) The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 95. Merck & Co. (MSD) Strategic initiatives
    Table 97. GlaxoSmithKline (GSK) Profiles
    Table 98. GlaxoSmithKline (GSK) The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 99. GlaxoSmithKline (GSK) The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 100. GlaxoSmithKline (GSK) Strategic initiatives
    Table 101. Bayer Profiles
    Table 102. Bayer The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 103. Bayer The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 104. Bayer Strategic initiatives
    Table 105. Takeda Profiles
    Table 106. Takeda The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 107. Takeda The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 108. Takeda Strategic initiatives
    Table 109. AstraZeneca Profiles
    Table 110. AstraZeneca The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 111. AstraZeneca The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 112. AstraZeneca Strategic initiatives
    Table 113. Novo Nordisk Profiles
    Table 114. Novo Nordisk The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 115. Novo Nordisk The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 116. Novo Nordisk Strategic initiatives
    Table 117. Teva Profiles
    Table 118. Teva The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 119. Teva The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 120. Teva Strategic initiatives
    Table 121. Bristol-Myers Squibb Profiles
    Table 122. Bristol-Myers Squibb The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 123. Bristol-Myers Squibb The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 124. Bristol-Myers Squibb Strategic initiatives
    Table 125. Boehringer Ingelheim Profiles
    Table 126. Boehringer Ingelheim The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 127. Boehringer Ingelheim The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 128. Boehringer Ingelheim Strategic initiatives
    Table 129. Allergan Profiles
    Table 130. Allergan The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 131. Allergan The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 132. Allergan Strategic initiatives
    Table 133. Eli Lilly Profiles
    Table 134. Eli Lilly The Influenza (Flu) Antiviral Drugs Product Introduction
    Table 135. Eli Lilly The Influenza (Flu) Antiviral Drugs Sales (Unit), Revenue (Million USD) (2017-2021)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
-Global The Influenza Antiviral Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
-Global The Influenza Antiviral Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
-Global The Influenza Antiviral Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports